ADVANTIO, INGENIO, VITALIO, FORMIO, ESSENTIO, ACCOLADE, PROPONENT, (INSIGNIA and ALTRUA 2
Boston Scientific Corp · Decision date Jul 1, 2026
What did the FDA approve?
FDA records N970003/S307 as a supplement to PMA null, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Jul 1, 2026.
FDA approval order statement
software changes for the LATITUDE NXT Patient Management System, Release 7.8
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Jul 1, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- N970003/S307
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- LWP
- Decision code
- APPR
- Decision date
- Jul 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implantable pulse generator, pacemaker (non-CRT).
- Applicant
- Boston Scientific Corp
- Product code
- LWP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
N970003/S307 received
Application receipt date recorded by FDA.
N970003/S307 · FDA decision
Real-Time Process
Related devices and submissions
Explore the linked device profile
Other records with product code LWP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA supplement | Oct 29, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA | |
| Medtronic, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Boston Scientific Corp | PMA supplement | Oct 3, 2026 | FDA | |
| Boston Scientific | PMA supplement | Oct 3, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 4100 Hamline Ave. N, St Paul, MN, 55112
Sources and methodology
- Original FDA record: N970003/S307
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
